NeOnc Technologies schedules FDA end-of-Phase 1 meeting for NEO212
The meeting is set for Nov. 17, 2026. The company said Phase 1 results showed durable disease control in two heavily pretreated brain cancer patients.
The meeting is set for Nov. 17, 2026. The company said Phase 1 results showed durable disease control in two heavily pretreated brain cancer patients.